Yahoo · Nov 19, 2026
Viridian Therapeutics' Lumvoa Emerging as Rival to Amgen's Tepezza, BofA Securities Says
Viridian Therapeutics' (VRDN) Lumvoa is emerging as a "credible" competitor to Amgen's (AMGN) Tepezz
NASDAQ · AMGN
Healthcare · Drug Manufacturers - General
$438.82
Down-$5.07 (-1.14%)
Updated Nov 20, 2026, 1:59 AM
SID Score
7.4/10
Composite research score
Smart Money
55/100
Neutral
Price performance · AMGN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
AMGN closed at $438.82 after 21 trading sessions, down 1.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $443.50 | $444.27 | $435.25 | $438.82 | 2.51M |
| Nov 18, 2026 | $453.525 | $455.09 | $441.625 | $443.89 | 2.59M |
| Nov 17, 2026 | $455.515 | $463.49 | $453.032 | $457.93 | 2.03M |
| Nov 16, 2026 | $472.75 | $474.40 | $461.72 | $462.32 | 1.93M |
| Nov 13, 2026 | $467.53 | $468.00 | $462.22 | $465.67 | 2.12M |
| Nov 12, 2026 | $471.86 | $474.00 | $466.92 | $467.06 | 2.83M |
| Nov 11, 2026 | $460.98 | $468.46 | $459.1379 | $468.11 | 2.01M |
| Nov 10, 2026 | $465.70 | $468.7999 | $459.45 | $465.23 | 2.14M |
| Nov 9, 2026 | $465.135 | $466.54 | $454.462 | $465.23 | 2.31M |
| Nov 6, 2026 | $448.165 | $462.91 | $447.04 | $460.42 | 2.58M |
| Nov 5, 2026 | $483.99 | $483.99 | $459.6488 | $460.28 | 4.11M |
| Nov 4, 2026 | $479.61 | $482.48 | $464.13 | $478.48 | 4.62M |
| Nov 3, 2026 | $463.38 | $467.04 | $460.15 | $461.26 | 2.38M |
| Nov 2, 2026 | $463.43 | $469.00 | $461.00 | $465.45 | 3.2M |
| Oct 30, 2026 | $470.15 | $475.645 | $465.33 | $466.01 | 3.29M |
| Oct 29, 2026 | $465.57 | $468.27 | $457.355 | $460.73 | 2.98M |
| Oct 28, 2026 | $441.03 | $454.66 | $439.57 | $451.83 | 2.91M |
| Oct 27, 2026 | $441.80 | $448.545 | $439.2801 | $447.95 | 1.73M |
| Oct 26, 2026 | $444.89 | $449.80 | $439.50 | $444.63 | 2.05M |
| Oct 23, 2026 | $444.40 | $444.59 | $439.07 | $439.26 | 2.07M |
| Oct 22, 2026 | $441.55 | $450.98 | $437.1944 | $447.28 | 3.11M |
The latest Smart Investors Daily articles mentioning AMGN.
Company
Market Activity
Research & News
AMGN research
Company profile and research snapshot.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 16, 2026 | Barclays | Equal-Weight | — |
| Nov 12, 2026 | Argus Research | Buy | — |
| Nov 6, 2026 | Freedom Broker | Hold | — |
| Nov 5, 2026 | Leerink Partners | Market Perform | — |
| Nov 5, 2026 | Guggenheim | Neutral | — |
No generated briefing is available yet.
Yahoo · Nov 19, 2026
Viridian Therapeutics' (VRDN) Lumvoa is emerging as a "credible" competitor to Amgen's (AMGN) Tepezz
SeekingAlpha · Nov 18, 2026
SCHD's price rose 31% in 12 months while its dividend grew just 2%, compressing the yield to around 3%.
Yahoo · Nov 18, 2026
Sneaker giant Nike failed to reassure investors about its turnaround strategy after extended earnings slump.
Yahoo · Nov 18, 2026
The fund added $176.7 million of stock in Monday's session, increasing 233 positions and trimming none.
Interpretive context generated from the platform’s current data sources.
Amgen Inc. shares closed at $443.89, reflecting a single-session decline of approximately 2.50% per SID market data. Despite this pullback, the stock has demonstrated consistent positive momentum across multiple timeframes, gaining 7.76% over the past month, 3.52% over three months, and 39.2% over the trailing twelve months. The current price sits above both the 50-day moving average of $427.10 and the 200-day moving average of $382.65, indicating a sustained uptrend according to Massive/Polygon technical data. The 14-day relative strength index reads 54.2, suggesting neither overbought nor oversold conditions. Amgen's beta of 0.472 reflects significantly lower volatility relative to the broader market, consistent with its positioning as a large-cap Healthcare name. Average daily trading volume stands at approximately 2.89 million shares, supporting adequate liquidity for institutional participants. The company's market capitalization is approximately $209.2 billion.
Amgen Inc. currently trades at a price-to-earnings ratio of 27.13, which positions the biotechnology giant at a premium relative to historical Healthcare sector averages, according to SID market data. The PEG ratio stands at 2.72, indicating that the stock's earnings growth rate does not fully justify its elevated P/E multiple on a growth-adjusted basis. The price-to-book ratio of 24.16 reflects a substantial premium to book value, a characteristic common among capital-light biopharmaceutical companies with significant intangible asset portfolios per SEC filings. Amgen offers a dividend yield of approximately 2.49%, providing an income component that distinguishes it from many biotechnology peers. With a market capitalization of $209.2 billion, Amgen remains one of the largest independent biotechnology firms globally. These valuation metrics collectively suggest the stock is priced for continued earnings execution and pipeline development rather than deep value considerations.
Amgen Inc. registers a composite smart money score of 55 out of 100 with a neutral signal overall, according to SID market data. The institutional component scores a perfect 25 out of 25, reflecting robust conviction among large asset managers and fund complexes. Insider activity scores 12.5 out of 25, with SEC Form 4 filings revealing four insider transactions over the past 90 days — all of which were purchases with zero insider sales recorded during the period. This unanimously bullish insider buying pattern suggests that corporate executives and directors view current price levels as attractive. Dark pool activity scores 8.5 out of 25, indicating moderate but not elevated off-exchange trading interest per 13F institutional filings. Congressional trading activity scores 8.8 out of 25, reflecting limited disclosed legislative trading in AMGN shares. The divergence between maximum institutional conviction and modest dark pool activity warrants monitoring, as institutional holders may be maintaining rather than actively accumulating positions at present levels.
Amgen Inc. has delivered four consecutive quarterly earnings beats, establishing a consistent pattern of outperformance relative to Wall Street consensus expectations per company earnings reports. The most recent quarter posted earnings per share of $6.45 against analyst estimates of $5.77, representing a positive surprise of $0.68, or approximately 11.8%. The prior quarter similarly exceeded expectations with EPS of $6.29 versus the $5.60 estimate, a $0.69 beat. Earlier quarters also showed positive surprises of $0.39 and $0.54, respectively, according to analyst estimates. The trend reflects accelerating outperformance, with the magnitude of earnings beats expanding from $0.39 to $0.69 across the four reported periods. Sequential EPS growth from $5.15 to $6.45 over four quarters demonstrates a meaningful earnings trajectory. This consistent ability to surpass consensus figures suggests either conservative Street modeling or stronger-than-anticipated operational execution across Amgen's commercial portfolio.
Recent Wall Street analyst activity on Amgen Inc. reflects a predominantly neutral consensus, according to SID consensus data. In November 2026, Barclays maintained its Equal-Weight rating, while Guggenheim and Leerink Partners reiterated Neutral and Market Perform ratings, respectively, per Wall Street analyst reports. Argus Research maintained a Buy rating, representing the most bullish stance among recent coverage updates. Notably, Freedom Broker downgraded AMGN from Buy to Hold, marking the only directional rating change in the recent cycle. Of the five most recent analyst actions, four were reiterations of existing ratings, suggesting the sell-side community has largely priced in Amgen's current fundamentals and near-term catalysts. The distribution skews neutral, with three firms at hold-equivalent ratings, one at Buy, and one recent downgrade to Hold. This measured positioning aligns with Amgen's premium valuation at a 27.13 P/E ratio, where analysts appear to acknowledge strong execution while questioning incremental upside from current levels.


The latest Smart Investors Daily articles mentioning AMGN.